外泌体及外泌体RNA在乳腺癌中的研究现状
本文综述外泌体及外泌体RNA(miRNA/LncRNA)在乳腺癌生物学与治疗中的潜在应用。文献显示外泌体通过转移miRNA和LncRNA参与乳腺肿瘤发生与进展,这些RNA通过转录后调控靶mRNA影响表达。迄今尚无临床批准的外泌体疗法,作者呼吁开展随机临床试验以推动临床转化。
要点
- 外泌体为30-150 nm脂质双层囊泡,参与乳腺肿瘤细胞间通讯。
- 外泌体miRNA/LncRNA通过转录后调控靶mRNA参与肿瘤发生与进展。
- 尚无临床批准的外泌体疗法,需随机临床试验验证其诊疗价值。
核心结论
- 外泌体及外泌体miRNA/LncRNA在乳腺癌诊断与治疗中具有潜在应用价值,但尚无临床批准的外泌体疗法。
研究设计与样本
- 本文为综述,汇总外泌体及外泌体RNA在乳腺癌生物学与治疗中的现有文献。
主要发现
- 外泌体由包括乳腺癌细胞在内的所有细胞类型释放,大小为30-150 nm。
- 外泌体通过转移miRNA和LncRNA在乳腺肿瘤发生与进展中发挥重要作用。
- 这些miRNA和LncRNA通过转录后调控靶mRNA导致表达调控或抑制。
- 过去二十年大量文献提示外泌体miRNA/LncRNA具有诊断和治疗应用前景。
临床怎么用
- 临床医生和肿瘤研究者应通过随机临床试验利用外泌体的优势,以改善乳腺癌管理。
局限性
- 迄今尚无临床批准的外泌体疗法,临床转化证据不足。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Improved treatment of breast cancer, the world's second most common cancer, requires identification of new sensitive prognostic and diagnostic biomarkers. Exosomes are lipid-bilayer extracellular vesicles of size 30-150 nm, released by all cell types, including breast cancer cells. Cellular communication is the primary function attributed to them. This review discusses the potential utility of exosomes and exosomal RNAs (microRNAs [miRNAs]/long non-coding RNAs [LncRNAs]) in breast cancer biology and treatment. The existing literature shows that exosomes play a significant role in breast tumorigenesis and progression through transfer miRNAs and LncRNAs. These miRNAs and LncRNAs function by post-transcriptionally regulating their target mRNAs, eventually leading to modulation of expression/repression. Over the past two decades, numerous publications point towards diagnostic and therapeutic applications of exosomal miRNAs/LncRNAs. Until now, we do not have clinically approved exosome-based therapeutics. Therefore, it is high time that clinicians and cancer researchers utilise exosome's benefits through randomised clinical trials for better management of breast cancer.
引用
- Lakshmi S, Hughes TA, Priya S, et al. Exosomes and exosomal RNAs in breast cancer: A status update. Eur J Cancer. 2020. PMID: 33373870. doi:10.1016/j.ejca.2020.11.033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。